Literature DB >> 11344041

Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate.

M Y Heo1, S J Sohn, W W Au.   

Abstract

Flavonoids are polyphenolic compounds that are present in plants. They have been shown to possess a variety of biological activities at non-toxic concentrations in organisms. Galangin, a member of the flavonol class of flavonoid, is present in high concentrations in medicinal plants (e.g. Alpinia officinarum) and propolis, a natural beehive product. Results from in vitro and in vivo studies indicate that galangin with anti-oxidative and free radical scavenging activities is capable of modulating enzyme activities and suppressing the genotoxicity of chemicals. These activities will be discussed in this review. Based on our review, galangin may be a promising candidate for cancer chemoprevention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344041     DOI: 10.1016/s1383-5742(01)00054-0

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  33 in total

1.  Molecular structure and anti-proliferative effect of galangin in HCT-116 cells: In vitro study.

Authors:  Ghassan Mohammad Sulaiman
Journal:  Food Sci Biotechnol       Date:  2016-02-29       Impact factor: 2.391

2.  Galangin, a dietary flavonoid, improves antioxidant status and reduces hyperglycemia-mediated oxidative stress in streptozotocin-induced diabetic rats.

Authors:  Amal A Aloud; Chinnadurai Veeramani; Chandramohan Govindasamy; Mohammed A Alsaif; Ahmed S El Newehy; Khalid S Al-Numair
Journal:  Redox Rep       Date:  2016-12-28       Impact factor: 4.412

3.  Anti-proliferative and apoptotic activities of constituents of chloroform extract of Juglans regia leaves.

Authors:  M Salimi; M H Ardestaniyan; H Mostafapour Kandelous; S Saeidnia; A R Gohari; A Amanzadeh; H Sanati; Z Sepahdar; S Ghorbani; M Salimi
Journal:  Cell Prolif       Date:  2014-01-27       Impact factor: 6.831

4.  Concentration-Dependent Protection by Ethanol Extract of Propolis against γ-Ray-Induced Chromosome Damage in Human Blood Lymphocytes.

Authors:  A Montoro; J F Barquinero; M Almonacid; A Montoro; N Sebastià; G Verdú; V Sahuquillo; J Serrano; M Saiz; J I Villaescusa; J M Soriano
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-11       Impact factor: 2.629

5.  Assessment of anti-mutagenic, anti-histopathologic and antioxidant capacities of Egyptian bee pollen and propolis extracts.

Authors:  Amany A Tohamy; Ehab M Abdella; Rasha R Ahmed; Yara K Ahmed
Journal:  Cytotechnology       Date:  2013-05-16       Impact factor: 2.058

6.  Galangin induces B16F10 melanoma cell apoptosis via mitochondrial pathway and sustained activation of p38 MAPK.

Authors:  Wenjing Zhang; Yan Lan; Qilai Huang; Zichun Hua
Journal:  Cytotechnology       Date:  2012-09-22       Impact factor: 2.058

7.  Inhibitory effect of the rhizomes of Alpinia officinarum on TPA-induced inflammation and tumor promotion in two-stage carcinogenesis in mouse skin.

Authors:  Ken Yasukawa; Yi Sun; Susumu Kitanaka; Naoyuki Tomizawa; Motofumi Miura; Shigeyasu Motohashi
Journal:  J Nat Med       Date:  2008-04-17       Impact factor: 2.343

8.  Synergistic effects of the combination of galangin with gentamicin against methicillin-resistant Staphylococcus aureus.

Authors:  Young-Seob Lee; Ok-Hwa Kang; Jang-Gi Choi; You-Chang Oh; Hee-Sung Chae; Jong Hak Kim; Hyun Park; Dong Hwan Sohn; Zheng-Tao Wang; Dong-Yeul Kwon
Journal:  J Microbiol       Date:  2008-07-05       Impact factor: 3.422

9.  Galangin Resolves Cardiometabolic Disorders through Modulation of AdipoR1, COX-2, and NF-κB Expression in Rats Fed a High-Fat Diet.

Authors:  Patoomporn Prasatthong; Sariya Meephat; Siwayu Rattanakanokchai; Juthamas Khamseekaew; Sarawoot Bunbupha; Parichat Prachaney; Putcharawipa Maneesai; Poungrat Pakdeechote
Journal:  Antioxidants (Basel)       Date:  2021-05-12

10.  Emerging roles of propolis: antioxidant, cardioprotective, and antiangiogenic actions.

Authors:  Julio Beltrame Daleprane; Dulcinéia Saes Abdalla
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.